Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Phase 2 Completed 15 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate sorafenib.

Timeline

Start: 2016-12-09
Primary completion: 2023-08-09
Completion: 2023-08-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elbasvir/Grazoprevir	Unknown	—	Oral
Subject	Pembrolizumab	Monoclonal antibody	—	Intravenous
Subject	Ribavirin	Small molecule	—	Oral

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications